NanoViricides seeks DR Congo regulator clearance for Phase II Ebola trial of NV-387 oral gummies

• NanoViricides filed with DRC regulator ACOREP seeking clearance to start a Phase II trial of NV-387 oral gummies for Bundibugyo Ebola.
• The company named Om Sai Clinical Research as CRO; it is also running NanoViricides’ Phase II mpox trial in the DRC.
• The filing comes during the DRC’s 17th Ebola outbreak, with more than 930 deaths and nearly 2,400 confirmed cases in two months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607220830ACCESSWRNAPR_____1194589) on July 22, 2026, and is solely responsible for the information contained therein.